X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
T22 is a world's first 3D printed gastric retention product. It is being evaluated in preclinical studies for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Lead Product(s): T22
Therapeutic Area: Cardiology/Vascular Diseases Product Name: T22
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Details:
T21 is Triastek’s third 3D printed oral colon-targeted delivery drug product, and is an oral, colon-targeted delivery drug for moderate to severe ulcerative colitis (UC).
Lead Product(s): T21
Therapeutic Area: Gastroenterology Product Name: T21
Highest Development Status: Phase IProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2023
Details:
T21 is a novel potential treatment capable of colon-targeted drug delivery. With a unique 3D dosage form design, T21 can reach the targeted colon segment of the GI tract.
Lead Product(s): T21
Therapeutic Area: Gastroenterology Product Name: T21
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
The novel design made possible by 3D printing allows T19 to function as a chronotherapeutic drug delivery system, targeting the circadian nature of RA symptoms.
Lead Product(s): T19
Therapeutic Area: Immunology Product Name: T19
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Matrix Partners China
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing July 14, 2021
Details:
United States Food and Drug Administration (FDA) has approved Triastek's Investigational New Drug (IND) 505(b)(2) application for its first 3D printed drug product – T19, indicated for the treatment of rheumatoid arthritis (RA).
Lead Product(s): T19
Therapeutic Area: Immunology Product Name: T19
Highest Development Status: IND EnablingProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
